Publications by authors named "Martin Torp Rahbek"

Claim this Profile
S
Screening real-world data for evidence of unsuspected drug benefits: An application of the sequence symmetry analysis.
Martin Torp Rahbek, Lars Christian Lund, Jesper Hallas

Br J Clin Pharmacol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network of doctors for multimorbidity and diabetes: Development of the NOMAD intervention - a multidisciplinary team for patients with diabetes and multimorbidity.
Stine Jorstad Bugge, Jørgen Hangaard, Per Damkier, Per Bruno Jensen, Sofie Lock Johansson, Martin Torp Rahbek

J Multimorb Comorb· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obtaining Valid Compatibility Intervals for Sequence Symmetry Analyses Utilizing Active Comparators: A Simulation Study.
Martin Torp Rahbek, Jesper Hallas, Lars Christian Lund

Pharmacoepidemiol Drug Saf· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased risk of hypereosinophilia following initiation of glucagon-like peptide 1 receptor agonist: A symmetry analysis using the Danish health registries.
Martin Torp Rahbek, Søren Andreas Just, Kasper Bruun Kristensen, Hussam Mahmoud Sheta, Jesper Hallas

J Intern Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Network of doctors for multimorbidity and diabetes - the NOMAD intervention: protocol for feasibility trial of multidisciplinary team conferences for people with diabetes and multimorbidity.
Stine Jorstad Bugge, Daniel Pilsgaard Henriksen, Per Damkier, Martin Torp Rahbek, Karoline Schousboe

Pilot Feasibility Stud· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is the sequence ratio an unbiased estimate of the incidence rate ratio? A simulation study.
Thomas Delvin, Sofie Egsgaard, Jesper Hallas, Helene Kildegaard, Lars Christian Lund, Martin Torp Rahbek

Pharmacoepidemiol Drug Saf· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case for screening real-world data for collateral drug benefits: Glucagon-like peptide 1 receptor agonists and bile acid diarrhea.
Martin Torp Rahbek, Lars Christian Lund, Jesper Hallas

Pharmacoepidemiol Drug Saf· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trend adjustment of the sequence difference when performing sequence symmetry analyses.
Martin Torp Rahbek, Jesper Hallas, Lars Christian Lund

Pharmacoepidemiol Drug Saf· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality and clinical outcomes following SARS-CoV-2 infection among individuals with haematological malignancies: A Danish population-based cohort study.
Lars Christian Lund, Martin Torp Rahbek, Peter Brown, Niels Obel, Jesper Hallas

Eur J Haematol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of Antiemetic Use After Initiation of Hormone Therapy.
Martin Torp Rahbek, Erika Björkström Gram, Jesper Hallas, Mette Marie Hougaard Christensen, Lars Christian Lund

JAMA Netw Open· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient plasma cobalamin elevation in patients with pneumonia - two case reports.
Martin Torp Rahbek, Rudolf Scheller, Mads Nybo, Jesper Ryg

Scand J Clin Lab Invest· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis